Analysis and interpretation of the issues facing Pharma: healthcare policy, public opinion, social trends, globalization, and more.
September 1, 2008
The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains
 |
June 1, 2008
By:Humphrey Taylor
This time, powerful interest groups (like pharma) that sank the Clinton healthcare bill are on the side of change
|
October 1, 2007
By:Humphrey Taylor
As I work with pharma companies, I'm often asked "When will we get major reform of the healthcare system?" and "What will the reformed system look like?" And sometimes "How will we get there?" This is not the same as asking "How should we reform the system?" Or "What should a reformed system look like?"
|
October 1, 2007
By:Charles Conrad Uy, Gerhard Symons
The first wealth is health, wrote American thinker Ralph Waldo Emerson. Indeed, history has taught us (even before Emerson) that health and wealth are inextricably linked—the more money one has, the healthier one is likely to be.
|
July 30, 2007
By:Peter Pitts
The US healthcare system may be broken, as such sages as Michael Moore suggest, but it's not likely to be fixed as long as our domestic debate remains stuck on the cost of prescription drugs. Meanwhile, obesity and diabetes are becoming national epidemics. Talk about sicko.
|
July 3, 2007
By:Humphrey Taylor
If pharma is seen as a genuine contributor to the policy debate on comparative effectiveness, it could influence funding, pricing, and coverage decisions
|
May 1, 2007
By:Humphrey Taylor
If I had a dollar for every time I heard the word crisis used to describe the healthcare system of one country or another, I would be rich. And with the '08 elections revving up, we can expect to hear a crisis chorus from many presidential and congressional candidates wise to the fact that healthcare often ranks as voters' No. 1 issue.
|
May 1, 2007
By:Peter Pitts
In march, us rep. rahm "Mr. Television" Emanuel (D-IL) reintroduced legislation aimed at what he calls "driving down the price of prescription drugs." But the only thing such legislation would accomplish would be the "driving down" of pharmaceutical innovation.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Conducting clinical trials in emerging regions can give you the edge. Five Quintiles experts share their insights into navigating the global regulatory landscape.